Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isodiol International Inc ISOLF

Healthcare Drug Manufacturers - Specialty & Generic Cannabis
Isodiol International Inc is a manufacturer and developer of phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds. It generates revenue from the sale of nutritional health products derived from hemp. Geographically, it derives a majority of revenue from the United States and also has a presence in Canada. Its product categories include Tinctures; Capsules; Topicals; Vape; Oral Spray; Skincare; and others.


GREY:ISOLF - Post by User

Isodiol International Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Blackgoldexperton Jun 15, 2018 11:50am
59 Views
Post# 28178057

RE:RE:RE:RE:RE:RE:RE:I bought Isodiol for it's Parabolic revenue growth

RE:RE:RE:RE:RE:RE:RE:I bought Isodiol for it's Parabolic revenue growthTrades at a discount to peers. Based on our F2018E sales estimate of $28.9M, ISOL trades at 5.1x 2018 EV/sales, a significant discount compared to intermediate peers (~$1B-$150M market cap), which trade at a median of 18.4x. Although Isodiol is focused on CBD-hemp, in our opinion the Companys share price is positively correlated to the general cannabis industry. We believe as Isodiol continues to increase revenue over the next few quarters, this gap should close. Of note, 2018 EV/sales multiples for the larger cannabis companies (Canopy, Aurora, MedReleaf, etc.) are in the range of 40-100x (8-25x in 2019) Read more at https://www.stockhouse.com/companies/bullboard?symbol=c.isol&postid=28177080#bluRWwO36HJxFhOH.99
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities